ACRIVON THERAPEUTICS INC (ACRV) Stock Income Statement
NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 85.30M | 67.10M | 32.66M | 16.18M | 3.17M | |||
| Research and Development | 60.84M | 46.02M | 23.95M | 13.72M | 1.87M | |||
| Selling, General, and Administrative Expenses | 24.46M | 21.08M | 8.71M | 2.47M | 1.30M | |||
| Operating Income | -85.30M | -67.10M | -32.66M | -16.18M | -3.17M | |||
| Interest Income/Expense | N/A | N/A | N/A | 0.00 | -2.10M | |||
| Other Income/Expense | 1.48M | 6.71M | 1.49M | -160.00K | -40.00K | |||
| Non Recurring Items | N/A | N/A | N/A | 100.00K | N/A | |||
| Income Before Taxes | -76.98M | -60.39M | -31.17M | -16.24M | -5.31M | |||
| Net Income | -76.98M | -60.39M | -31.17M | -16.24M | -5.31M | |||
| EBITDA | -84.45M | -66.57M | -32.30M | -16.14M | -3.16M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.70 | -2.74 | -1.42 | -0.78 | -0.25 | |||
| Non GAAP EPS | -2.70 | -2.73 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD